Literature DB >> 34554341

Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision.

Alison Laws1,2,3, Fisher Katlin1, Faina Nakhlis1,2,3, Sona A Chikarmane3,4, Stuart J Schnitt2,3,5, Tari A King6,7,8.   

Abstract

BACKGROUND: Based on modern series demonstrating low upgrade rates for pure lobular neoplasia (LN) diagnosed on core needle biopsy (CNB), our institution no longer recommends routine excision, provided imaging is concordant. This study describes outcomes in patients managed without surgical excision.
METHODS: From an institutional database, we identified all patients with a diagnosis of pure atypical lobular hyperplasia and/or classic lobular carcinoma in situ on CNB managed without surgical excision (i.e., conservative management) from 2015 to 2019. The primary outcome of interest was failure of conservative management, defined as development of ipsilateral same-quadrant ductal carcinoma in situ or invasive breast cancer within 2 years of CNB, or need for ipsilateral same-quadrant excisional biopsy. We also evaluated rates of ipsilateral same-quadrant CNB during follow-up.
RESULTS: Among 96 pure LN lesions on CNB since 2015, 80 (83%) were managed without surgical excision. Median follow-up was 27 months (IQR: 16-28), with only 2 (2%) patients lost to follow-up. No patients developed an ipsilateral, same-quadrant breast cancer. The 3-year risk of conservative management failure was 6.2% (95% CI 2.3-15.7%). All failures were a result of need for excisional biopsy due to progressive imaging abnormalities at the initial CNB site, with benign final pathology. The 3-year risk of ipsilateral same-quadrant CNB was 9.2% (95% CI 3.8-21.5%).
CONCLUSION: Non-surgical management of pure LN is safe, and the likelihood of requiring subsequent surgical excision or repeat CNB during follow-up is low. These data provide reassurance that routine excision of pure LN in the setting of radiologic-pathologic concordance is not required.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2021        PMID: 34554341     DOI: 10.1245/s10434-021-10827-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Lobular carcinoma in situ: A rare form of mammary cancer.

Authors:  F W Foote; F W Stewart
Journal:  Am J Pathol       Date:  1941-07       Impact factor: 4.307

  1 in total
  2 in total

Review 1.  The morphologic spectrum of lobular carcinoma in situ (LCIS) observations on clinical significance, management implications and diagnostic pitfalls of classic, florid and pleomorphic LCIS.

Authors:  Edi Brogi
Journal:  Virchows Arch       Date:  2022-05-14       Impact factor: 4.064

2.  Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS.

Authors:  Faina Nakhlis; Fisher D Katlin; Samantha C Grossmith; Ashley DiPasquale; Beth T Harrison; Stuart J Schnitt; Tari A King
Journal:  Ann Surg Oncol       Date:  2022-06-30       Impact factor: 4.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.